In HTA-driven environments, stability in reimbursement positioning often reflects persistence of structural constraints rather than absence of progress.

Following a structured surveillance reassessment, the MARA Rating for baxdrostat in treatment-resistant hypertension has been affirmed at B+ (Very Weak) in April 2026. The rating remains unchanged from its prior determination in September 2025.

This action reflects continued alignment across key domains. Clinical Effectiveness remains supported by evidence of blood pressure reduction, and Safety and Adverse Effects continues to show a favorable profile. However, the reimbursement signal remains constrained by unresolved factors within Comparator Appropriateness, Cost-Effectiveness, and Health-Related Quality of Life.

The absence of active comparator evidence against guideline-relevant therapies continues to limit comparative positioning under HTA scrutiny. In parallel, the lack of published economic evaluation and HRQoL data sustains uncertainty in cost-utility anchoring. These elements maintain sensitivity to pricing assumptions and payer interpretation.

The affirmation indicates that, while evidence has matured incrementally, it has not materially altered the balance of reimbursement determinants within the MARA framework.

This action reflects reimbursement probability under HTA frameworks, not regulatory viability.

MARA ratings are continuously monitored and updated when material evidence emerges.